These 8 Biotechs Are In This Week’s Spotlight
This week, the annual meeting of the American Diabetes
Association should focus the spotlight on many companies
developing new drug treatments for diabetes (see last weekGÇÖs
biotech piece). Diabetes is a growing problem,
particularly in children, and costs this countryGÇÖs healthcare
system billions of dollars. Despite being effective, todayGÇÖs
treatment
Another Medical Conference Friday — Here Are Some Companies To Watch
The biotechs have experienced a nice run since March, a run fueled by anticipated positive news out of the recent ASCO meeting.-áWell, the meeting did not disappoint the medical profession
Here’s Why I’m Watching These Six Biotech Stocks
Starting today, the 6th Annual Meeting of the American Society of Gene Therapy begins in Washington, DC, and with it begins more potential trading opportunities. This meeting, although not as popular as ASCO, is sexier than ASCO by way of its content. It brings together scientists and companies to discuss the latest cutting-edge research in gene therapy for a variety of diseases. The presentations at this meeting are pushing the envelope in applying gene therapy to the treatment of disease.
And The Early Winner Is…
The American Society of Clinical OncologyGÇÖs annual meeting began this past weekend, and so far the early winner appears to be Genentech (DNA), on many fronts.-á
Several Important Meetings Coming Soon — Here’s What I’m Looking At
Let the ASCO games begin. It looks like the ASCO floodgates have busted wide open, based on yesterdayGÇÖs biotechGÇÖs wild ride.-á The momentum all started last week with GenentechGÇÖs (DNA) release of-á positive phase III data on its new anti-angiogenesis drug.-á The instigator yesterday was ImClone (IMCLE), with a news release before the opening bell.-á The company stated it would receive a $6 million milestone payment from its European partner Merck KGaA related to the upcoming release of phase III
Why Anything Can Happen In Biotech This Week
It is only four days before the biggest meeting of
cancer specialists in the worldGǪ..and anything can
happen. Last Monday, Genentech (DNA) could not keep its
secret locked up any longer. On Monday morning, the
company fired the first preemptive shot by releasing positive
survival data on its new anti-angiogenesis drug Avastin for
the treatment
Is There More To Come From These Companies?
Will yesterdayGÇÖs wild ride for Genentech end?-áYesterday, the company initiated a preemptive release of crucial phase III data on its developing anti-angiogenesis drug Avastin a week before the start of this yearGÇÖs ASCO meeting.-áIt was a thing of beauty and caught everyone off gu
Four Big Stocks To Watch Before A Big Meeting
The 39th annual gathering of the American Society of Clinical Oncology (ASCO) is only eleven days away (May 31 to June 3) and already Wall Street speculation is brewing on which company will the toast of the meeting.-áThe ASCO meeting is the largest of the year for cancer specialists to present
Why Genentech Is In Play Today
Genentech announced this morning before the bell that a Phase III trial testing their new drug Avastin with chemotherapy improved overall survival in previously untreated patients with metastatic colorectal cancer.-áThis is significant news.-áAvastin is a monoclonal antibody aimed at a
FDA Panel Decision Is Good For These Three Stocks
After trading hours yesterday, an FDA Advisory panel unanimously approved a novel approach to treating asthma, a disease that affects millions of people worldwide. Genentech (DNA), Novartis (NOV), and the small biotech
Add These Two Biotech Stocks To Your Watchlist
Conservative numbers show erectile dysfunction to
affect over 30 million men in this country and over 130
million worldwide. The current market for drugs to treat
ED is over $1.5 billion and expects to climb to $5 billion in
three years. Obviously, this target disease is a large
market with
Lots Of Biotech Opportunities This Week…Here Are A Few
This week and next could prove to be very busy for stocks in
the biotech sector, for two reasons. As I mentioned in my
last article, on May 15 a FDA Advisory Panel will decide the
fate of the drug Xolair, a new approach to the treatment of
asthma in adolescents and adults. Three companies are
developing the drug: Tanox (TNOX), Genentech (DNA), and
Novartis (NVS). The PanelGÇÖs meeting on Thursday has all the
earmarking